3-Bromopyruvic acid| CAS 1113-59-3

Cas No.:	1113-59-3
Chemical Name:	3-Bromopyruvic acid
Synonyms:	3-Bromopyruvic acid;3-BROMO-2-OXOPROPANOIC ACID;3-BROMO-2-OXOPROPIONIC ACID;BROMOPYRUVIC ACID;3-bromo-2-oxo-propanoicaci;3-bromopyruvate;beta-bromopyruvicacid;bromopyruvate;bromo-pyruvicaci;3-BROMOPYRUVIC ACID CRYSTALLINE;Bromopyruvicacidhydrate;3-BROMO-2-OXOPROPANOICACID(3-BROMOPYRUVICACID);2-Oxo-3-bromopropanoic acid;2-Oxo-3-bromopropionic acid;3-BROMO-2-OXO-PROPIONIC ACID;3-BromopYHuvic acid;3-BROMOPYRUVIC ACID HYDRATE;3-BROMOPYRUVICACID(3-BROMOPYRUVATE);Hexokinase II Inhibitor II, 3-BP;PROPANOIC ACID,3-BROMO-2-OXO-;3-Bromo-2-oxopropionic Acid;NS00023565;NS00023565;EN300-67360;EN300-67360;CHEBI:95046;CHEBI:95046;Bromopyruvic acid; 3-bromo-2-oxopropanoic acid;Bromopyruvic acid; 3-bromo-2-oxopropanoic acid;Bromopyruvic acid, >=97.0% (T);Bromopyruvic acid, >=97.0% (T);3-bromo-2-oxopropanoic acid;3-Bromopyruvic acid;3-bromo-2-oxopropanoic acid;3-Bromopyruvic acid;bromopyruvic acid;bromopyruvic acid;3-BP;3-BP;.beta.-Bromopyruvic acid;NSC-62343;.beta.-Bromopyruvic acid;NSC-62343;EINECS 214-206-5;NSC 11731;EINECS 214-206-5;NSC782120;NSC 11731;FT-0623262;NSC782120;BRD-K92980438-001-01-7;FT-0623262;BRD-K92980438-001-01-7;Z1079181768;Z1079181768;Bromopyruvicacid;Bromopyruvicacid;Hexokinase II Inhibitor II, 3-BP - CAS 1113-59-3;Hexokinase II Inhibitor II, 3-BP - CAS 1113-59-3;3-Bromo-2-oxopropionic acid;3-Bromo-2-oxopropionic acid;NSC-11731;NSC-11731;Propanoic acid, 3-bromo-2-oxo-;3-bromo-2-oxo-propionic acid;Propanoic acid, 3-bromo-2-oxo-;J-650255;3-bromo-2-oxo-propionic acid;J-650255;1113-59-3;1113-59-3;BPV;BPV;CS-5517;NSC11731;CS-5517;Q3608257;NSC11731;NSC62343;Q3608257;3-BrPA;NSC62343;MFCD00002587;3-BrPA;Pyruvic acid, bromo-;HY-19992;MFCD00002587;3-Bromopyruvic acid hydrate,98;Pyruvic acid, bromo-;HY-19992;B1153;SCHEMBL8126;3-Bromopyruvic acid hydrate,98;bromo-2-oxopropanoic acid;B1153;beta-Bromopyruvic acid;SCHEMBL8126;s5426;bromo-2-oxopropanoic acid;AM84337;beta-Bromopyruvic acid;AS-16146;s5426;AKOS015892643;AM84337;63JMV04GRK;AS-16146;NSC 62343;AKOS015892643;63JMV04GRK;3-bromopyruvic acid;HMS3866H13;NSC 62343;CCG-266336;3-bromopyruvic acid;Hexokinase II Inhibitor II;3-BP;HMS3866H13;J-511892;CCG-266336;UNII-63JMV04GRK;Hexokinase II Inhibitor II;3-BP;BRN 1746786;J-511892;3-Bromo-2-oxopropanoic acid #;UNII-63JMV04GRK;CHEBI:131461;BRN 1746786;3-bromo-2-oxopropanoic acid;3-Bromo-2-oxopropanoic acid #;3-bromo-2-keto-propionic acid;CHEBI:131461;NSC-782120;3-bromo-2-oxopropanoic acid;HMS3741K19;3-bromo-2-keto-propionic acid;3-bromopyruvicacid;NSC-782120;DTXSID7040940;HMS3741K19;CHEMBL177837;3-bromopyruvicacid;NCIOpen2_000241;DTXSID7040940;CHEMBL177837;NCIOpen2_000241
SMILES:	O=C(O)C(CBr)=O
Formula:	C₃H₃BrO₃
M.Wt:	166.96
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A glycolytic inhibitor that inhibits hexokinase II activity, suppresses ATP production, and induces endoplasmic reticulum (ER) stress; potentiates acetate-induced apoptosis and anti-proliferative effect in CRC cells; abrogates MUC1-mediated radiation resistance both in vitro and in vivo pancreatic cancer models, by reducing glucose flux into nucleotide biosynthetic pathways and enhancing DNA damage.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.